Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Stock Slips 5.21 Percent on Q2 Earnings

NEW YORK, Aug. 9 (GenomeWeb News) - Shares in Sequenom were down 5.21 percent, or $.05, at $.91 in mid-afternoon trading after the company yesterday reported a slight increase in second-quarter revenues as losses slid sharply on lower costs.

 

As GenomeWeb News reported last night, Sequenom posted a rise in second-quarter revenues to $6.2 million, versus $6 million in the year-ago quarter, an increase the company attributed to both the addition of new customers and the upgrading of the firm's analysis systems by existing customers.

 

Sequenom's research and development spending dropped to about $3 million in the quarter from $5.7 million a year earlier.

 

The company posted a net loss of $6 million, or $.15 per share, versus a year-ago loss of $9.8 million, or $.25 per share.

As of June 30, Sequenom had cash, cash equivalents, short-term investments, and restricted cash totaling $25.4 million.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more